A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors
This study tests an experimental drug called JAB-2485 in adults with advanced solid tumors, including certain types of breast and lung cancers. The goal is to see if this medicine is safe and helps stop cancer cells from dividing by blocking a specific protein.
You may be eligible if you have advanced cancer that has stopped responding to standard treatments and you are able to carry out normal daily activities. You will also need to provide a stored tumor sample and meet specific heart health and infection-free requirements.
Participants will receive the study drug, JAB-2485, while doctors closely monitor their safety, overall health, and how the medicine affects their tumors using regular imaging scans. Your medical team will guide you through every step and check in on you often.
The study is currently active and recruiting participants at medical centers in Detroit, Michigan; St. Louis, Missouri; and Dallas, Texas. Speak with your doctor to see if one of these locations is a good fit for you.
- 1Evaluating the safety of a new drug called JAB-2485 for advanced solid tumors
- 2Open to adults whose previous cancer treatments have stopped working
- 3Currently recruiting patients at multiple locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.